Get the Stockscreener App
8.50
0.59%
0.05
Ocular Therapeutix Inc stock is traded at $8.50, with a volume of 1.29M.
It is up +0.59% in the last 24 hours and down -3.19% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$8.45
Open:
$8.31
24h Volume:
1.29M
Relative Volume:
1.15
Market Cap:
$1.34B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-7.0833
EPS:
-1.2
Net Cash Flow:
$-90.59M
1W Performance:
-2.19%
1M Performance:
-3.19%
6M Performance:
+39.80%
1Y Performance:
+116.84%
1-Day Range:
$8.31
$8.62
1-Week Range:
$8.15
$9.21
52-Week Range:
$3.7599
$11.78
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.50 | 1.34B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
Investors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past week - Yahoo Finance
How to Take Advantage of moves in (OCUL) - Stock Traders Daily
Wellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Last Week's Biggest Stock Movers: Mylan, Ocular Therapeutix - AOL
Ocular Therapeutix Insiders Sold US$1.0m Of Shares Suggesting Hesitancy - Simply Wall St
Fmr LLC Purchases 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Ocular Therapeutix Grants Major Stock Awards Package to New Executive, Including 285K Shares - StockTitan
Verition Fund Management LLC Purchases Shares of 62,501 Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Ocular Therapeutix CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Charles Schwab Investment Management Inc. Has $9.66 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Point72 Asset Management L.P. Trims Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
492,900 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Bought by Polar Asset Management Partners Inc. - MarketBeat
235,498 Shares in Ocular Therapeutix, Inc. (NASDAQ:OCUL) Purchased by Patient Square Capital LP - MarketBeat
Erste Asset Management GmbH Makes New $2.05 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Keratoconus Market to Reach New Heights in Growth by 2032, DelveInsight Predicts | Glaukos Corporation, iVeena Delivery Systems, Ocular Therapeutix - Barchart
Expert Outlook: Ocular Therapeutix Through The Eyes Of 4 Analysts - Inkl
Ocular Therapeutix announces over 300 subjects randomized in SOL-1 - Yahoo Finance
Ocular Pokes Ahead on Randomized Subjects - Baystreet.ca
Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1 - The Manila Times
Braidwell LP Has $19.49 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) is Knoll Capital Management LLC's 10th Largest Position - MarketBeat
OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 29, 2024) - GuruFocus.com
Neuropathic Ocular Pain Market Is Booming Worldwide 2024-2031 | - openPR
Acuta Capital Partners LLC Cuts Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
OCUL (Ocular Therapeutix) 9-Day RSI : 56.85 (As of Nov. 28, 2024) - GuruFocus.com
Learn to Evaluate (OCUL) using the Charts - Stock Traders Daily
Ocular Therapeutix chief scientific officer sells shares worth $26,561 By Investing.com - Investing.com Nigeria
Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock By Investing.com - Investing.com Canada
Ocular Therapeutix CEO Pravin Dugel sells $186,326 in stock - Investing.com India
Ocular Therapeutix chief development officer sells shares worth $26,101 By Investing.com - Investing.com Nigeria
Ocular Therapeutix chief development officer sells shares worth $26,101 - Investing.com
Ocular Therapeutix executive sells shares for $16,326 - Investing.com
Ocular Therapeutix executive sells shares for $16,326 By Investing.com - Investing.com Australia
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ocular Therapeutix chief scientific officer sells shares worth $26,561 - Investing.com
Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences - GlobeNewswire
Ocular Therapeutix to Present Clinical Data at Major Healthcare Conferences in December - StockTitan
OCUL (Ocular Therapeutix) EBITDA per Share : $-1.15 (TTM As of Sep. 2024) - GuruFocus.com
Banco Santander S.A. Sells 205,137 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Hypertension Pipeline Forecast 2024: FDA Approvals, - openPR
Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates - MSN
Ocular Therapeutix Q3 2024 Earnings Preview - MSN
(OCUL) Technical Data - Stock Traders Daily
Ocular Therapeutix Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
GSA Capital Partners LLP Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (NASDAQ:OCUL) Given New $15.00 Price Target at HC Wainwright - MarketBeat
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Q3 2024 Earnings Call Transcript - Insider Monkey
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Ocular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ... - Yahoo Finance
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):